Literatūras saraksts

Byzova T.V., Plow E.F. 2000. The PlA2 allele and cardiovascular disease: the pro33 and con. - The Journal of Clinical Investigation, 105: 697-698.

Gregg D., Clermont P.J.G. 2003. Platelets and Cardiovascular Disease. – Circulation, 108: e88-90.

Jackson S.P., Schoenwaelder S.M. 2003. Antiplatelet therapy: in search of the ‘magic bullet’. - Nature Reviews Drug Discovery, 2: 775-789.

Lefkovits J., Plow E.F., Topol. E.J. 1995. Platelet glycoprotein IIb/III a receptors in cardiovscular medicine. – The New England journal of medicine. 332: 1553 - 1557.

Mikkelson J., Perola M., Karhunen P.J. 2005. Genetics of ptatelet glycoprotein receptors: risk of trombotic events and pharmacogenetic implications. - Clinical and applied thrombosis/hemostasis, 11: 113-125.

Newman P.J., Derbes R.S., Aster R.H. 1988. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. - The Journal of Clinical Investigation, 83: 1178-1781.

Ruggeri Z.M. 2002. Platelets in atherothrombosis. - Nature Medicine, 8: 1227-1233.

Zimrin A.B., Gidwitz S., Lord S., Schwartz E., Bennett J.S. 1990. The genomic organization of platelet glycoprotein IIIa. – The Journal of Biological Chemistry, 265: 8590-8595.

Baiba Krivmane